January 2017 Volume 13, Issue 1
Volume 13, Issue 1 | January 2017
January 2017
In this Issue
Clinical Trials
MPC-HSC synergy vs. cancer
MD Anderson and NIH fund trial combining Mesoblast technologies for rapid engraftment of stem cell transplantsOrchard’s efforts bear fruit
U.K.-based company receives $20 million for clinical trial of ADA-SCIDGetting control of bleeding
Spark and Pfizer announce updated data for ongoing hemophilia B studyMaking a dent in advanced refractory cancer
Corvus’ CPI-444 shows promise for disabling a tumor’s ability to subvert attack by the immune systemAlopexx presents encouraging lymphoma results
Data for Phase 1 study of DI-Leu16-IL2 in relapsed/refractory NHL presented at ASH 2016Discovery
Hope for rare diseases
Illumina kicks off iHope initiative for undiagnosed childrenBristol-Myers Squibb and Enterome join forces
Companies announce oncology deal around discovery of immunotherapy agents and biomarkers‘Modulating’ tumor treatment
Albumedix and NYU School of Medicine team up to target novel cellular pathways in oncologyTargeting genetically defined neurodegenerative diseases
Sharp Edge Labs enters into drug discovery collaboration with Sumitomo Dainippon PharmaHeptares gains G7 Therapeutics
Acquisition is aimed at extending leadership in GPCR- focused drug discovery and developmentResearch & Development
Building better models of organs
QGel’s designer matrices promising for organoid culture and cancer therapy developmentA circadian component to cancer?
Disruption in circadian rhythms might be implicated in other unexpected disease areas, too, like diabetes and sepsisDeciphering immune response
French researchers offer new global approach for predicting individual immune responsesMolecular motor has a ‘gear’ for directional switching
Research aids understanding of complex cellular machinery used to ensure normal cell divisionAbbVie partners with Johns Hopkins and Northwestern on cancer research
Pair of five-year collaboration deals announced on the same day look to be headed in similar directionsFeature
SLAS2017 Show Preview: Putting together a ‘Capitol’ event
SLAS2017 will bring a wealth of scientific and other programming to Washington, D.C., in FebruarySpecial Reports
Special Report on Microbiomics: The aliens within us
As if human diversity wasn’t tricky enoughCommentary
Publishers’ commentary: From an amazing 2016 to a promising 2017
Reviewing the past year and highlighting what's to come in DDNewsOut of Order: Undaunted
Life sciences in general, and pharma/biotech along with it, moves fast, and our hats are off to the researchers who are trying to keep paceGuest Commentary: Sample-handling automation
The big changes still coming, and how to adapt to a changing worldDiagnostics
Resisting antibiotic resistance
OpGen, Merck to develop rapid-fire diagnostics and informatics to combat antibiotic resistanceTwice the power for two-gene test
Clinical Genomics’ ctDNA blood test outperforms CEA in detecting colorectal cancer recurrence‘Knowing is key’
New saliva test aims to predict future onset of Alzheimer’s diseaseSequencing of events
A quick roundup of some late-2016 genomics-based diagnostics newsContract Services
Meaningful marriage
Bionical acquires Emas to deliver improved health outcomesA multitude of models
CrownBio introduces new in-vivo platforms for renal researchImproving clinical trial efficiency
Medpace selects Montrium Connect EDMS to make clinical trials more efficient and support continued global business growthEnvigo invests in STAG
Envigo announced in fall 2016 the launch of a dedicated Science and Technology Advisory GroupPreclinical
Hope for hemophiliacs
New research into subcutaneous factor replacement therapy could offer IV alternativeA new treatment combo for RCC
Preclinical data demonstrate functional activity of AGS-003-like therapy in kidney cancer murine modelNo lack of potential for NK cells
Affimed shares preclinical data on AFM13, AFM11, trispecific antibodiesKura presents data on KO-947 and menin-MLL in Munich
Company targets first half of 2017 for a trial of KO-947, describes as a ‘potent inhibitor’ of ERKBusiness & Government Policy
Spin out and launch
Celgene acquires Acetylon, which spins out RegenacyOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsTenaya Therapeutics launches to go after heart disease
With $50M investment, Gladstone Institutes look to push basic science discoveries toward cures for heart diseaseFollow-up data on Imbruvica at ASH 2016
Findings show strong, lasting efficacy of Imbruvica through five years of treatment for CLL/SLLPatent Docs: Solicitor General recommends that the Supreme Court review Federal Circuit decision in Sandoz v. Amgen
These recommendations are significant, because the Supreme Court asks the government for its views under those circumstances inter alia where there are important policy considerations at stake
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Overcoming barriers in gene therapy
Advanced gene editing, delivery, and analytical tools are driving better gene therapies.
A multiomic approach to profiling brain tumors
Probing the molecular drivers of brain metastasis reveals novel therapeutic targets.
Enhancing immune cell profiling with digital technologies
Software innovations help researchers decode immune complexity in cancer.
